GemVax&KAEL Co.,Ltd. (KOSDAQ:082270)

GemVax&KAEL Statistics

Total Valuation

GemVax&KAEL has a market cap or net worth of KRW 2.15 trillion. The enterprise value is 2.21 trillion.

Market Cap	2.15T
Enterprise Value	2.21T

Important Dates

The last earnings date was Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

GemVax&KAEL has 41.97 million shares outstanding. The number of shares has increased by 0.78% in one year.

Current Share Class	41.97M
Shares Outstanding	41.97M
Shares Change (YoY)	+0.78%
Shares Change (QoQ)	+0.23%
Owned by Insiders (%)	1.46%
Owned by Institutions (%)	3.48%
Float	31.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	31.48
PB Ratio	52.63
P/TBV Ratio	56.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-33.74
EV / Sales	32.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-83.03

Financial Position

The company has a current ratio of 0.60, with a Debt / Equity ratio of 1.78.

Current Ratio	0.60
Quick Ratio	0.47
Debt / Equity	1.78
Debt / EBITDA	n/a
Debt / FCF	-2.74
Interest Coverage	-3.75

Financial Efficiency

Return on equity (ROE) is -107.03% and return on invested capital (ROIC) is -11.70%.

Return on Equity (ROE)	-107.03%
Return on Assets (ROA)	-9.01%
Return on Invested Capital (ROIC)	-11.70%
Return on Capital Employed (ROCE)	-22.58%
Revenue Per Employee	375.81M
Profits Per Employee	-359.24M
Employee Count	192
Asset Turnover	0.45
Inventory Turnover	5.99

Taxes

Income Tax	-859.32M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +406.56% in the last 52 weeks. The beta is 1.03, so GemVax&KAEL's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	+406.56%
50-Day Moving Average	56,105.00
200-Day Moving Average	36,588.60
Relative Strength Index (RSI)	43.52
Average Volume (20 Days)	173,436

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GemVax&KAEL had revenue of KRW 68.40 billion and -65.38 billion in losses. Loss per share was -1,632.93.

Revenue	68.40B
Gross Profit	23.27B
Operating Income	-21.71B
Pretax Income	-66.24B
Net Income	-65.38B
EBITDA	-17.27B
EBIT	-21.71B
Loss Per Share	-1,632.93

Balance Sheet

The company has 20.04 billion in cash and 72.81 billion in debt, giving a net cash position of -52.77 billion or -1,257.28 per share.

Cash & Cash Equivalents	20.04B
Total Debt	72.81B
Net Cash	-52.77B
Net Cash Per Share	-1,257.28
Equity (Book Value)	40.91B
Book Value Per Share	995.50
Working Capital	-26.20B

Cash Flow

In the last 12 months, operating cash flow was -24.09 billion and capital expenditures -2.48 billion, giving a free cash flow of -26.57 billion.

Operating Cash Flow	-24.09B
Capital Expenditures	-2.48B
Free Cash Flow	-26.57B
FCF Per Share	-632.99

Margins

Gross margin is 34.02%, with operating and profit margins of -31.73% and -95.59%.

Gross Margin	34.02%
Operating Margin	-31.73%
Pretax Margin	-96.85%
Profit Margin	-95.59%
EBITDA Margin	-25.25%
EBIT Margin	-31.73%
FCF Margin	n/a

Dividends & Yields

GemVax&KAEL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.78%
Shareholder Yield	n/a
Earnings Yield	-3.04%
FCF Yield	-1.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GemVax&KAEL has an Altman Z-Score of 4.06 and a Piotroski F-Score of 1.

Altman Z-Score	4.06
Piotroski F-Score	1